Adaptyv Biosystems Secures $40 Million in Latest Series A Funding Round

Adaptyv Biosystems secured $40 million in its latest Series A, adding another data point to the FinTech funding market.

Adaptyv Biosystems Raises $40 million in Funding

Adaptyv Biosystems Raises $40M in Series A Funding. Founded in 2021 by Julian Englert, CEO, and Daniel Nakhaee-Zadeh, CTO, Adaptyv Bio develops a cloud-connected, high-throughput automated wet lab platform engineered to serve as the physical execution layer for agentic biology.

Investors Behind the Funding

The round was backed by Highland Europe. Capvizr tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

Adaptyv Biosystems operates in FinTech. Adaptyv Biosystems's financing adds to recent private-market activity.

Strategic Use of Funds

Double its engineering and scientific workforce at its Lausanne headquarters, finance the construction and operational deployment of a new physical laboratory facility in London in.

Looking Ahead

biological gigafactory,

Source reference: original announcement/article.